The original sins of clinical trials with intravenous immunoglobulins in sepsis

نویسندگان

  • Raquel Almansa
  • Eduardo Tamayo
  • David Andaluz-Ojeda
  • Leonor Nogales
  • Jesús Blanco
  • Jose Maria Eiros
  • Jose Ignacio Gomez-Herreras
  • Jesus F Bermejo-Martin
چکیده

Intravenous immunoglobulins (IVIGs) have not yet demonstrated robust evidence in the benefit for treatment of sepsis. In spite of multiple clinical trials performed with IVIG in sepsis, it remains an experimental therapy for this severe condition. Nonetheless, these trials do not address a number of potential confounding factors, concerning both the patient and the IVIG preparations, which could greatly affect the final result. To name a few, endogenous levels of immunoglobulin isotypes and subclasses are not assessed prior to treatment. The presence/absence of patient antibodies against the microorganism(s) causing sepsis is not evaluated. The accuracy of antibiotic prescription is not included as an adjusting variable. The degree of patient immunosuppression (previous or induced by sepsis) is not documented. In turn, the concentration and antimicrobial specificities of the antibodies contained in the batches of IVIG are not assessed. Neither the pharmacokinetics of IVIG nor its potential immunomodulatory effects are evaluated. In addition, the concept of 'window of opportunity' for IVIG administration following diagnosis of sepsis is not considered. In conclusion, addressing these factors could help to individualise treatment with IVIG for sepsis, which could enhance the opportunities of this drug to show benefits in terms of survival in this severe condition.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Adjuvant use of intravenous immunoglobulin in the treatment of neonatal sepsis: a systematic review with a meta-analysis.

OBJECTIVE To evaluate whether intravenous immunoglobulin reduces mortality and length of hospital stay in the treatment of neonatal sepsis. SOURCES The MEDLINE database was searched. The keywords were combined using the following search strategy: [(sepsis OR shock, septic OR infection) AND immunoglobulins, intravenous] AND infant, newborn. Only randomized clinical trials (RCTs) showing good m...

متن کامل

Three cases of systemic lupus erythematosus and review of the mechanisms concerning treatment with intravenous immunoglobulins (IVIG).

The systemic lupus erythematosus (SLE) is an autoimmune disorder with a broad array of clinical signs. In this research, we aimed to use intravenous immunoglobulins (IVIG) called intacglobin as monotherapy to manage an SLE in three patients. Laboratory investigations for SLE diagnosis were done, including the detection of anti-nuclear antibodies (ANA) and SLE confirmation by detecting high tite...

متن کامل

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

BACKGROUND Mortality from sepsis and septic shock remains high. Results of trials on intravenous immunoglobulins (IVIG) as adjunctive therapy for sepsis have been conflicting. This is an update of a Cochrane review that was originally published in 1999 and updated in 2002 and 2010. OBJECTIVES To estimate the effects of IVIG as adjunctive therapy in patients with bacterial sepsis or septic sho...

متن کامل

Varicella Exposure in Neonatal Intensive Care Unit in a Low Resource Country: Successful Prophylaxis with Intravenous Immunoglobulins

Background: Varicella-zoster infection is a serious and potentially fatal disease, especially among newborns.Several studies have described postnatal varicella zoster exposure among neonates and reported on the efficacy of varicella-zoster immunoglobulins (VZIG) used as post-exposure prophylaxis. Unfortunately, VZIG is not available in Jordan. A limited number of studies have investigated the e...

متن کامل

Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis.

PURPOSE OF REVIEW Systemic infections in premature and term infants cause significant morbidity and mortality in spite of appropriate antimicrobial therapy. Consequently, immunotherapy has emerged as a potential adjuvant therapeutic modality to reduce the incidence and mortality associated with neonatal sepsis. RECENT FINDINGS The most recent findings during the review period include systemat...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 19  شماره 

صفحات  -

تاریخ انتشار 2015